Clinical Trial Update: A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase II study evaluating GFH375 in KRAS G12D-mutant metastatic pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• GFH375 (GFH375)

Snippet

Sponsor: Genfleet Therapeutics (Shanghai) Inc. | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: WITHDRAWN